

In re Application of:
Twardzik, *et. al.*
Application No.: 10/050,190
Filed: January 15, 2002
Page 3

PATENT
ATTY. DOCKET NO.: STEM1110-5

REMARKS


By the present amendment, Applicant respectfully requests incorporation of the attached Sequence Listing into the application.

CONCLUSION

The Examiner is invited to contact Applicants' undersigned representative if there are any questions regarding the subject application. The Commissioner is authorized to debit (or credit) Deposit Account No. 50-1355 if any fee is required (or if there is any overpayment).

Respectfully submitted,

Date: September 17, 2004



Lisa A. Haile, J.D., Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
USPTO Customer Number: 28213

PATENT
ATTY. DOCKET NO.: STEM1110-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Twardzik, *et. al.* Art Unit: 1647
Parent Serial No.: 09/641,587 Examiner: Unassigned
Parent Filing Date: August 18, 2000
Serial No.: 10/050,190
Filed: January 15, 2002
Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

COPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR TRANSFER OF COMPUTER READABLE FORM

Sir:

The above-identified patent application lacks a paper copy of the Sequence Listing for inclusion into the specification, as well as a computer readable form of the Sequence Listing. Applicants respectfully direct the attention of the Office to the following:

1. The paper copy of the Sequence Listing in this application, is identical to the computer readable copy of the Sequence Listing filed in application 09/641,587, filed August 18, 2000. In accordance with 37 CFR 1.821(e), please use the first filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included in a separately filed preliminary amendment for incorporation into the specification.

CERTIFICATION UNDER 37 CFR §1.6(d)	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below	
<u>CARA GRIFONE</u>	
(Name of person transmitting paper)	
<u>Cara Grifone</u>	September 17, 2004
(Signature)	(Date)

Gray Cary\GT\6415591.1
105265-21

In re Application of:

Twardzik, *et. al.*

Application No.: 10/050,190

Filed: January 15, 2002

Page 2


PATENT

ATTY. DOCKET NO.: STEM1110-5

2. I hereby state that the submission, filed in accordance with 37 CFR 1.821(g), herein does not include new matter. Applicants submit that the foregoing satisfies the requirements of Rule §1.821. If there are any questions regarding this response, the Office is invited to contact the undersigned.

No fee is deemed necessary in connection with the filing of this paper. However, if any fee is required, the Commissioner is hereby authorized to charge the amount of this fee, or credit any overpayments, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: September 17, 2004

Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

USPTO Customer Number 28213
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

1

SEQUENCE LISTING

<110> STEM CELL PHARMACEUTICALS, INC.
TWARDZIK, Daniel R.
PERNET, Andre
FELKER, Thomas S.
PASKELL, Stefan

COPY

<120> TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE
THEREFOR

<130> STEM1110-2

<140> US 09/641,587

<141> 2000-08-17

<150> US 09/559,248

<151> 2000-04-26

<150> US 09/459,813

<151> 1999-12-13

<150> US 09/492,935

<151> 2000-01-27

<150> US 09/378,567

<151> 1999-08-19

<160> 7

<170> PatentIn version 3.1

<210> 1

<211> 50

<212> PRT

<213> Homo sapiens

<400> 1

Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
35 40 45

Leu Ala
50

<210> 2

<211> 50

<212> PRT

<213> Rattus norvegicus

<400> 2

2

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu
35 40 45

Asp Ala
50

<210> 3
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> A modified human TGF-alpha sequence

<400> 3

Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
1 5 10 15

Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
20 25 30

Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
35 40 45

Arg Cys Glu His Ala Asp Leu Leu Ala
50 55

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Modified human TGF alpha sequence fragment

<220>
<221> MISC_FEATURE
<222> (1)..(10)
<223> Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa at
residue 6 is Y or F; and Xaa at residue 10 is R or K

<400> 4

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

3

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Modified human TGF alpha sequence fragment

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is V, G,
or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

<400> 5

Xaa His Xaa Xaa Xaa Xaa Xaa
1 5

<210> 6
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Modified human TGF alpha sequence fragment

<220>
<221> MISC_FEATURE
<222> (1)..(18)
<223> Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa at
residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,
15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue
17 is D or E

<400> 6

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Modified human TGF alpha sequence fragment

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue 7 is
K or D

4

<400> 7

Xaa Xaa Ser His Phe Asn Xaa
1 5